RSCM
SRPT icon

Rock Springs Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Rock Springs Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-53,300
Closed -$2.06M – 131
2015
Q4 		$2.06M Buy
+53,300
New +$1.73M 0.16% 109

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Rock Springs Capital Management's SRPT Position: Q3 2025 in Review

Rock Springs Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 68,600 shares — an estimated $1.17M sold.

Rock Springs Capital Management first reported a position in SRPT in Q4 2015 and held it in 39 quarters. The position peaked at $61M in Q1 2023. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Rock Springs Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Rock Springs Capital Management sold 68,600 Sarepta Therapeutics shares in Q3 2025, an estimated $1.17M.
  • Rock Springs Capital Management first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 39 quarters.
  • Rock Springs Capital Management's Sarepta Therapeutics position peaked at $61M in Q1 2023.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.